(CercleFinance.com) – AstraZeneca announced on Monday that Enhertu, the antibody-conjugate it is developing with the Japanese Daiichi Sankyo, had given positive results in a trial conducted on patients suffering from breast cancer advanced.
The biopharmaceutical group indicates that the phase III study has reached its primary endpoint by significantly improving, both in clinical and statistical terms, the survival time of patients without progression of the disease.
The secondary objective of the trial, improving overall patient survival, was also achieved.
The trial, called ‘Destiny-Breast02’ aimed to compare the efficacy of Enhertu against a treatment of choice favored by doctors in the treatment of so-called ‘HER2 positive’, unresectable and/or metastatic breast cancer in patients already treated with Kadcyla from Roche.
AstraZeneca plans to present this data at an upcoming medical conference.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
